Sumit Chanda

Last updated

Sumit K. Chanda is an American research scientist who works on viral and immunological human diseases. [1] He also led the team that built and deployed Metascape for the analysis of omics data. [2] This tool attracts over 500,000 users per year and has been cited 2,000 times a year since its inception in 2019.[ not verified in body ]

Contents

Early life and education

Chanda earned his B.Sc. in biology at Cornell University and his Ph.D. in molecular pharmacology at Stanford University. He completed his postdoctoral training at the Genomics Institute of the Novartis Research Foundation, [3] where he pioneered high-throughput approaches for target identification and validation that enabled preclinical development of novel therapeutics. [4]

Career

In 2014, Chanda, along with Bin Zhou, Yingyao Zhou, Max Chang, Lars Pache and Chris Benner created a free gene annotation and analysis resource called Metascape. [5]

He returned to academic research at Sanford Burnham Prebys Medical Discovery Institute in 2007, where he became director of their Immunity and Pathogenesis program, [6] and joined the Immunology and Microbiology Department at the Scripps Research Institute and Calibr as professor in 2021. [7]

Chanda developed and applied large-scale systems-based approaches to identify host factors critical for viral replication, including influenza, SARS-CoV-2, [8] flaviviruses and HIV-1. His team deployed high-throughput technologies for the discovery of antiviral therapies in response to the COVID-19 pandemic [9] and discovered a novel class of latency reversal agents for an HIV-1 cure (3).

Chanda leads several large, multi-institutional collaborative efforts including the Center for Antiviral Medicines (CAMPP), [10] which is a part of the NIAID Antiviral Drug Discovery (AViDD) network, as well as the Reversing Immune Dysfunction for HIV-1 Eradication Program (RID-HIV), which is a member of the National Institutes of Health's Martin Delaney Collaboratories for HIV Cure Research (MDC) program. [11]

Publications

Related Research Articles

<span class="mw-page-title-main">Antiviral drug</span> Medication used to treat a viral infection

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are a class of antimicrobials, a larger group which also includes antibiotic, antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies. Most antivirals are considered relatively harmless to the host, and therefore can be used to treat infections. They should be distinguished from virucides, which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees.

<span class="mw-page-title-main">Entecavir</span> Chemical compound

Entecavir (ETV), sold under the brand name Baraclude, is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection. In those with both HIV/AIDS and HBV antiretroviral medication should also be used. Entecavir is taken by mouth as a tablet or solution.

<span class="mw-page-title-main">APOBEC3G</span> Protein and coding gene in humans

APOBEC3G is a human enzyme encoded by the APOBEC3G gene that belongs to the APOBEC superfamily of proteins. This family of proteins has been suggested to play an important role in innate anti-viral immunity. APOBEC3G belongs to the family of cytidine deaminases that catalyze the deamination of cytidine to uridine in the single stranded DNA substrate. The C-terminal domain of A3G renders catalytic activity, several NMR and crystal structures explain the substrate specificity and catalytic activity.

Long-term nonprogressors (LTNPs), are individuals infected with HIV, who maintain a CD4 count greater than 500 without antiretroviral therapy with a detectable viral load. Many of these patients have been HIV positive for 30 years without progressing to the point of needing to take medication in order not to develop AIDS. They have been the subject of a great deal of research, since an understanding of their ability to control HIV infection may lead to the development of immune therapies or a therapeutic vaccine. The classification "Long-term non-progressor" is not permanent, because some patients in this category have gone on to develop AIDS.

<span class="mw-page-title-main">Telbivudine</span> Chemical compound

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo and Tyzeka. Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. However, HBV signature resistance mutation M204I or L180M+M204V have been associated with Telbivudine resistance.

<span class="mw-page-title-main">PQBP1</span> Protein-coding gene in the species Homo sapiens

Polyglutamine-binding protein 1 (PQBP1) is a protein that in humans is encoded by the PQBP1 gene.

<span class="mw-page-title-main">APOBEC3C</span> Protein-coding gene in humans

DNA dC->dU-editing enzyme APOBEC-3C is a protein that in humans is encoded by the APOBEC3C gene.

<span class="mw-page-title-main">Tetherin</span> Mammalian protein found in Homo sapiens

Tetherin, also known as bone marrow stromal antigen 2, is a lipid raft associated protein that in humans is encoded by the BST2 gene. In addition, tetherin has been designated as CD317. This protein is constitutively expressed in mature B cells, plasma cells and plasmacytoid dendritic cells, and in many other cells, it is only expressed as a response to stimuli from IFN pathway.

<span class="mw-page-title-main">SAMHD1</span>

SAM domain and HD domain-containing protein 1 is a protein that in humans is encoded by the SAMHD1 gene. SAMHD1 is a cellular enzyme, responsible for blocking replication of HIV in dendritic cells, macrophages, monocytes and resting CD4+ T lymphocytes. It is an enzyme that exhibits phosphohydrolase activity, converting deoxynucleoside triphosphates (dNTPs) to inorganic phosphate (iPPP) and a 2'-deoxynucleoside (i.e. deoxynucleosides without a phosphate group). In doing so, SAMHD1 depletes the pool of dNTPs available to a reverse transcriptase for viral cDNA synthesis and thus prevents viral replication. SAMHD1 has also shown nuclease activity. Although a ribonuclease activity was described to be required for HIV-1 restriction, recent data confirmed that SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity.

Peptide T is an HIV entry inhibitor discovered in 1986 by Candace Pert and Michael Ruff, a US neuroscientist and immunologist. Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), a drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding and infection of viral strains which use the CCR5 receptor to infect cells.

Adolfo García-Sastre,(born in Burgos, 10 October 1964) is a Spanish professor of Medicine and Microbiology and co-director of the Global Health & Emerging Pathogens Institute at the Icahn School of Medicine at Mount Sinai in New York City. His research into the biology of influenza viruses has been at the forefront of medical advances in epidemiology.

<span class="mw-page-title-main">APOBEC3H</span> Protein-coding gene in the species Homo sapiens

DNA dC->dU-editing enzyme APOBEC-3H, also known as Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3H or APOBEC-related protein 10, is a protein that in humans is encoded by the APOBEC3H gene.

<span class="mw-page-title-main">Peter Palese</span> American microbiologist and virologist

Peter Palese is a United States microbiologist, researcher, inventor and the Horace W. Goldsmith Professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai in New York City, and an expert in the field of RNA viruses.

The term co-option refers to the capacity of intracellular parasites to use host-cell proteins to complete their vital cycle. Viruses use this mechanism, as their genome is small.

Metascape is a free gene annotation and analysis resource that helps biologists make sense of one or multiple gene lists. Metascape provides automated meta-analysis tools to understand either common or unique pathways and protein networks within a group of orthogonal target-discovery studies.

Gary J. Nabel is an American virologist and immunologist who is President and chief executive officer of ModeX Therapeutics in Natick, Massachusetts. He was the founding director of Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.

<span class="mw-page-title-main">Elizabeth A. Winzeler</span> American microbiologist

Elizabeth Ann Winzeler is an American microbiologist and geneticist. She is a professor in the Division of Host-Microbe Systems and Therapeutics of the School of Medicine at the University of California at San Diego. Although she works in a variety of different disease areas, most research focuses on developing better medicines for the treatment and eradication of malaria.

<span class="mw-page-title-main">Azvudine</span> Antiviral drug

Azvudine is an antiviral drug which acts as a reverse transcriptase inhibitor. It was discovered for the treatment of Hepatitis C and has since been investigated for use against other viral diseases such as AIDS and COVID-19, for which it was granted conditional approval in China.

Francis "Frank" Vincent Chisari is a physician, experimental pathologist, virologist, and immunologist, known for his research on virus-host interactions of hepatitis B and hepatitis C.

ORF6 is a gene that encodes a viral accessory protein in coronaviruses of the subgenus Sarbecovirus, including SARS-CoV and SARS-CoV-2. It is not present in MERS-CoV. It is thought to reduce the immune system response to viral infection through interferon antagonism.

References

  1. ↑ Chanda, Sumit (2023-02-21). "How can we prepare for the next pandemic? Sumit Chanda Podcast Highlights" (Interview). Scripps Research . Retrieved 2023-09-22– via YouTube.
  2. ↑ Zhou, Yingyao; Zhou, Bin; Pache, Lars; Chang, Max; Khodabakhshi, Alireza Hadj; Tanaseichuk, Olga; Benner, Christopher; Chanda, Sumit K. (2019-04-03). "Metascape provides a biologist-oriented resource for the analysis of systems-level datasets". Nature Communications. 10 (1): 1523. doi: 10.1038/s41467-019-09234-6 . ISSN   2041-1723. PMC   6447622 .
  3. ↑ "Novartis Institutes for BioMedical Research". Novartis . Retrieved 2023-09-22.
  4. ↑ "Sumit K. Chanda Inventions, Patents and Patent Applications - Justia Patents Search". Justia . Retrieved 2023-09-22.
  5. ↑ Metascape. "The Brief History of Metascape Since 2014 | Metascape Blog" . Retrieved 2023-09-28.
  6. ↑ Weintraub, Arlene (Apr 20, 2020). "COVID-19: New animal data back up Gilead's remdesivir as other treatment candidates emerge". Fierce Biotech.
  7. ↑ "Sumit Chanda". Scripps Research . Retrieved 2023-09-22.
  8. ↑ "Meet the authors: Laura Martin-Sancho and Sumit K. Chanda" (PDF). Molecular Cell . June 17, 2021.
  9. ↑ "High-throughput screening reveals 21 drugs with activity against COVID-19" (Press release). Retrieved 2023-09-22– via Drug Target Review.
  10. ↑ "NIAID Announces Antiviral Drug Development Awards". National Institute of Allergy and Infectious Diseases (Press release). 2022-05-18. Retrieved 2023-09-22.
  11. ↑ Chanda, Sumit. "Sumit Chanda - From HIV to Covid-19 (EP.01)". Model Medicines (Interview). Retrieved 2023-09-22.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.